All In Biotech

NDA 216338 · Teva Pharms INC

Paclitaxel

Paclitaxel · Intravenous · Microtubule Inhibitor

Last checked: Nov 19, 2026Latest source record: Nov 21, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

May 11, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5,298

1,055 Phase 3, 888 recruiting

FAERS reports

84,326

81,765 serious, 11,621 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE MYELOSUPPRESSION Do not administer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) therapy to patients who have baseline neutrophil counts of less than 1,500 cells/mm 3 . [see Contraindications ( 4 )] . Monitor for neutropenia, which may be severe and result in infection or sepsis, [see Warnings and Precautions ( 5.1 , 5.3 )] . Perform frequent complete blood cell counts on all patients receiving Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) [see Contraindications ( 4 ), Warnings and Precautions ( 5.1 , 5.3 )]. WARNING: SEVERE MYELOSUPPRESSION See full prescribing information for complete boxed warning. Do not administer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) therapy to patients with baseline neutrophil counts of less than 1,500 cells/mm 3 . ( 4 ) Monitor for neutropenia,...

What it is approved for

From the label in effect Nov 1, 2023.

Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) 1.1 Metastatic Breast Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. 1.2 Non-Small Cell Lung Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. 1.3 Adenocarcinoma of the Pancreas Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.

Mechanism: Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 21, 2023 Supplement 1 · Efficacy LabelLetter
  • May 11, 2023 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • PACLITAXEL · PACLITAXEL 100MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Paclitaxel" as an intervention, any sponsor and status, largest first.

All 5,298 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea4,733
  • dyspnoea4,676
  • neutropenia4,628
  • off label use4,561
  • diarrhoea4,383
  • anaemia4,036
  • malignant neoplasm progression3,938
  • myelosuppression3,678
  • disease progression3,478
  • fatigue3,475
  • neuropathy peripheral3,433
  • pyrexia3,235

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004626
2005832
2006599
2007576
2008812
2009968
2010990
20111,649
20122,062
20132,215
20141,795
20152,370
20162,931
20173,194
20184,835
20194,669
20204,850
20215,551
20227,668
20238,071
20249,609
202510,146
20267,307

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Paclitaxel (Paclitaxel)

2024 spending

$204K

Beneficiaries

677

2,204 claims

Per beneficiary

$302

$1.45 per unit

View as table
YearSpending
2020$98,284
2021$163,501
2022$203,935
2023$208,100
2024$204,442

Part B: Paclitaxel (Paclitaxel) · HCPCS J9267

2024 spending

$1.4M

Beneficiaries

15,291

88,539 claims

Per beneficiary

$94

2024 ASP limit $0.10 per unit

View as table
YearSpending
2020$2,617,492
2021$2,610,744
2022$1,955,616
2023$1,934,625
2024$1,436,827

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,214 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.